FindMyKOL

Jie Wang, MD

Enriched profile

Hematology / Oncology

ORCIDNone on fileNPI↗
✓ Itemized profile
Region🇺🇸 Philadelphia, PA · Northeast · United StatesSpecialtyHematology / OncologyFocusLung Cancer (NSCLC/SCLC)+10
Active KOLFindMyKOL type: RegionalLatest publicationNone indexedOnline presenceNone verifiedPayments2022–2025NIH fundingNone on fileWhy? →

Jie Wang is a Lung Cancer (NSCLC/SCLC) physician. ClinicalTrials.gov lists 55 registered studies with this person as an investigator.

Data verified 27 Oct 2026

Overview

Updated 28 Oct 2026

Jie Wang, MD, is profiled from the public federal record. It also documents an investigator role on 55 registered clinical trials, industry payments reported by 12 companies.

  • Top research focus: Lung Cancer (NSCLC/SCLC)
  • 55 registered trials on ClinicalTrials.gov
  • Open Payments reporting from 12 companies

Generated from the cited public record · current as of 28 Oct 2026. Every fact links its source below.

Indications focus

from trials led + research topics
Lung Cancer (NSCLC/SCLC)24 trialsSmall Cell Lung Carcinoma18 trialsCoronary Artery Disease / ACS5 trialsColorectal Cancer3 trialsHead & Neck Cancer3 trialsRectal Neoplasms3 trialsHIV3 trialsHIV Infections3 trialsAcquired Immunodeficiency Syndrome3 trialsCoronary Artery Disease2 trialsGastroesophageal Cancer1 trialStomach Neoplasms1 trialHelicobacter Infections1 trialESRD / Dialysis1 trialGlomerular Disease1 trialCoronary Stenosis1 trialConstriction, Pathologic1 trialDepression (MDD)1 trialPain1 trialChronic Pain1 trialStress Disorders, Post-Traumatic1 trialParkinson's Disease1 trialHuntington Disease1 trialAlzheimer's / Dementia1 trialCognitive Dysfunction1 trialChronic Kidney Disease1 trialNeoplasm Metastasis1 trialBrain Neoplasms1 trialCarcinoma, Squamous Cell1 trialEsophageal Squamous Cell Carcinoma1 trialPleural Effusion1 trialPleural Effusion, Malignant1 trialLymphoproliferative Disorders1 trialCarcinoma, Pancreatic Ductal1 trialCarcinoma, Ductal1 trialLymphoma1 trialLymphoma, T-Cell, Peripheral1 trialLymphoma, T-Cell1 trialCarcinoma, Small Cell1 trialAdenocarcinoma of Lung1 trialMalnutrition1 trialAngina, Stable1 trialAngina, Unstable1 trial

Research focus

OpenAlex concept fingerprint
Lung Cancer (NSCLC/SCLC)Small Cell Lung CarcinomaColorectal CancerRectal NeoplasmsAdenocarcinoma of LungBrain NeoplasmsGastroesophageal CancerHead & Neck CancerNeoplasm MetastasisPleural Effusion, MalignantStomach Neoplasms

Drugs & molecules

across trials, industry payments and publications
Beleodaqgeneric · BelinostatClinical trials—Industry payments15Publications—Poteligeogeneric · MogamulizumabClinical trials—Industry payments3Publications—Adcetrisgeneric · Brentuximab vedotinClinical trials—Industry payments1Publications—Breyanzigeneric · Lisocabtagene maraleucelClinical trials—Industry payments1Publications—Brukinsageneric · ZanubrutinibClinical trials—Industry payments1Publications—Gamifantgeneric · EmapalumabClinical trials—Industry payments1Publications—Reblozylgeneric · LuspaterceptClinical trials—Industry payments1Publications—Vonjogeneric · PacritinibClinical trials—Industry payments1Publications—Voraxazegeneric · GlucarpidaseClinical trials—Industry payments1Publications—

Works with

trial sponsors and companies reporting payments
Acrotech Biopharma Inc.Clinical trials—Industry payments14Guang'anmen Hospital of China Academy of Chinese Medical SciencesClinical trials8Industry payments—Cancer Institute and Hospital, Chinese Academy of Medical SciencesClinical trials7Industry payments—Kyowa Kirin, Inc.Clinical trials—Industry payments4Chang Gung Memorial HospitalClinical trials3Industry payments—Shanghai Henlius BiotechClinical trials3Industry payments—AkesoClinical trials2Industry payments—Allist Pharmaceuticals, Inc.Clinical trials2Industry payments—AstraZenecaClinical trials2Industry payments—Jun LiClinical trials2Industry payments—Peking University Cancer Hospital & InstituteClinical trials2Industry payments—Suzhou Puhe Pharmaceutical Technology Co., LTDClinical trials2Industry payments—Wang . Jiun-JieClinical trials2Industry payments—Acrotech Biopharma LLCClinical trials—Industry payments1Alpha Biopharma (Jiangsu) Co., Ltd.Clinical trials1Industry payments—BeiGeneClinical trials1Industry payments—BeiGene USA, Inc.Clinical trials—Industry payments1Beijing Mabworks Biotech Co., Ltd.Clinical trials1Industry payments—Betta Pharmaceuticals Co., Ltd.Clinical trials1Industry payments—Biotech Pharmaceutical Co., Ltd.Clinical trials1Industry payments—BTG International Inc.Clinical trials—Industry payments1Celgene CorporationClinical trials—Industry payments1CTI BioPharma Corp.Clinical trials—Industry payments1E.R. Squibb & Sons, L.L.C.Clinical trials—Industry payments1Eastern Cooperative Oncology GroupClinical trials1Industry payments—Fudan UniversityClinical trials1Industry payments—Hutchison Medipharma LimitedClinical trials1Industry payments—Innovent Biologics (Suzhou) Co. Ltd.Clinical trials1Industry payments—JemincareClinical trials1Industry payments—Jie WangClinical trials1Industry payments—

Scholarship

indexed output and impact (OpenAlex)
View publications ↓
0h-index

Hirsch index, productivity × impact (OpenAlex).

Clinical & industry

trials, payments and federal funding
55clinical trials

Investigator role on registered studies.

View trials ↓
12companies · 2022–2025

Companies reporting payments to CMS. Facts, not judgments.

View payments ↓
0NIH grants

Federally funded research awards.

Contact

The practice address and phone this provider lists in the federal NPPES (CMS) registry.

Practice address

Telephone

Practice address and telephone from the federal NPPES registry.

Sign in to view contact details →

Clinical trials

Updated 28 Oct 2026

Listed as an investigator on 55 registered studies on ClinicalTrials.gov. The most recent:

All 55 trial records: search, sort and filter.Explore →

Industry payments

Updated 28 Oct 2026

12 companies reported payments to CMS in program years 2022–2025. These are public disclosures, not judgments. The latest:

All 15 payment records: search, sort and filter.Explore →
View the CMS Open Payments record ↗

Medicare prescribing footprint (2024)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Cancer & immunology

    43.5%
    Kinase inhibitor28.6%
    Brukinsa50%Imbruvica50%
    Part D<11 patients
    Folate Analog Metabolic Inhibitor14.9%
    Methotrexate100%
    Part D<11 patients

  • Metabolism & gastrointestinal

    28%
    Corticosteroid19%
    Prednisone100%
    Part D≥16 patients
    Serotonin-3 Receptor Antagonist8.9%
    Ondansetron Hcl100%
    Part D≥13 patients

  • Dermatology

    12.5%
    Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor12.5%
    Acyclovir100%
    Part D≥13 patients
All 5 therapeutic areas: search, sort and filter.Explore →
Where care is delivered (Part B)34.4% facility · 65.6% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

NIH funding

We didn't find any NIH-funded research awards for this person in NIH RePORTER. Why? →

Publications

None on file yet. We only list publications we can confidently match to this person. Why? →

Similar KOLs

Other experts from the same institution or the same specialty.